FDA Approves Biosimilar Insulin Product Rezvoglar
Rezvoglar is a long-acting human insulin analogue.
Diagnosis & Disease Information
Incidence of Treatment Deintensification After Severe Hypoglycemic Episode Examined
This retrospective study aimed to determine the incidence of treatment deintensification in a real-world setting.
Skytrofa, a Once-Weekly Therapy for Pediatric Growth Hormone Deficiency, Now Available
The approval was based on data from the phase 3 heiGHt trial, which compared Skytrofa to somatropin in 161 treatment-naïve, prepubertal patients with growth hormone deficiency.
Skytrofa Approved as Once-Weekly Growth Hormone Deficiency Therapy
The approval was based on data from the phase 3 heiGHt trial that assessed Skytrofa in 161 treatment-naïve, prepubertal patients with growth hormone deficiency.
Additional Dosing Options of Tirosint-SOL Now Available
Tirosint-SOL is approved for the treatment of hypothyroidism and for pituitary thyrotropin suppression.
FDA Clears FreeStyle Libre 2 App to Monitor Glucose Levels
By scanning the glucose sensor with the app, users will be able to receive their current glucose level, trend arrow, and glucose history.
Semglee Approved as First Interchangeable Biosimilar Insulin Product
Semglee (insulin glargine) may be substituted for the reference product, Lantus, at the pharmacy counter and without the intervention of the prescriber.
FDA Approves Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy
Nevro’s SCS system for painful diabetic neuropathy will be available under the brand name HFX™ for PDN.
Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease
The approval was based on data from the phase 3 FIDELIO-DKD trial.
FDA Panel Votes on Teplizumab for the Delay of Type 1 Diabetes
Teplizumab is an investigational anti-CD3 monoclonal antibody.
- Loading...
Loading...
Loading... 
Loading...